Breakthrough Products

Renibus is a clinical stage biopharmaceutical company with two Phase 3 clinical assets, dedicated to treating, improving, and extending patients’ lives by developing products to prevent disease progression, improve outcomes and protect against organ damage associated with cardio, renal and metabolic diseases.

Renibus’ lead program is Veverimer, an oral, non-absorbed polymer that binds hydrochloric acid in the GI tract, designed to increase serum bicarbonate without adding sodium. that may provide benefit in treating metabolic acidosis diseases with an unmet medical need. Veverimer is advancing into a Phase 3 clinical trial (REVIVE) for the treatment of patients with chronic kidney disease and metabolic acidosis. The trial is expected to commence in early 2026 and will enroll approximately 150 participants.

Renibus is also developing RBT-1 a novel pharmacologic preconditioning agent to reduce the risk ofpost-op complications in patients undergoing cardiac surgery. While the PROTECT Phase 3 trial did not meet its primary endpoint, post-hoc analysis indicates higher risk patients were more likely to benefit from RBT-1 treatment with a primary benefit being reduced time in the ICU. Renibus is currently evaluating potential further development of RBT-1 in risk-enriched patients, including plans to confirm regulatory requirements with FDA.

Renibus has three additional assets at earlier stages of development. Learn more about our approach and our pipeline.